Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Stephen P SallowayLee A HonigbergWilliam ChoMichael WardMichel FriesenhahnFlavia BrunsteinAngelica QuartinoDavid ClaytonDeborah MortensenTobias BittnerCarole HoChristina RabeStephen P SchauerKristin R WildsmithReina N FujiShehnaaz SulimanEric M ReimanKewei ChenRobert PaulPublished in: Alzheimer's research & therapy (2018)
ClinicalTrials.gov, NCT01397578 . Registered on 18 July 2011.